<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>neurodegenerative lipid metabolism &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/neurodegenerative-lipid-metabolism/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 17 Sep 2025 16:36:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>neurodegenerative lipid metabolism &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Study Explores the Link Between Lipid Metabolism and Parkinson’s Disease</title>
		<link>https://bioengineer.org/new-study-explores-the-link-between-lipid-metabolism-and-parkinsons-disease/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 17 Sep 2025 16:36:48 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[CNS lipid homeostasis]]></category>
		<category><![CDATA[ferroptosis in Parkinson's]]></category>
		<category><![CDATA[neurodegenerative lipid metabolism]]></category>
		<category><![CDATA[Parkinson's disease lipidomics]]></category>
		<category><![CDATA[α-Synuclein aggregation mechanisms]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-study-explores-the-link-between-lipid-metabolism-and-parkinsons-disease/</guid>

					<description><![CDATA[Parkinson’s Disease (PD), a debilitating neurodegenerative disorder affecting more than 10 million people globally, continues to challenge scientists and clinicians alike due to its complex pathology and lack of curative treatments. Characterized primarily by classic motor symptoms—such as tremors, bradykinesia, rigidity, and postural instability—PD’s underlying mechanisms delve far beyond dopamine deficiency and Lewy body formations, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">269936</post-id>	</item>
		<item>
		<title>Lipid Imbalance in Brain Drives Parkinson’s Dyskinesia</title>
		<link>https://bioengineer.org/lipid-imbalance-in-brain-drives-parkinsons-dyskinesia/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 23 Aug 2025 11:41:56 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[brain lipid imbalance]]></category>
		<category><![CDATA[L-DOPA-induced dyskinesia]]></category>
		<category><![CDATA[neurodegenerative lipid metabolism]]></category>
		<category><![CDATA[Parkinson’s disease dyskinesia]]></category>
		<category><![CDATA[primate model Parkinson’s research]]></category>
		<guid isPermaLink="false">https://bioengineer.org/lipid-imbalance-in-brain-drives-parkinsons-dyskinesia/</guid>

					<description><![CDATA[Emerging Insights into Lipid Dysregulation Illuminate Mechanisms Underlying L-DOPA-Induced Dyskinesia in Parkinson’s Disease Parkinson’s disease (PD) continues to challenge neuroscientists and clinicians alike, with its complex pathology and the often problematic side effects of standard treatment protocols. At the forefront of therapeutic strategies lies L-DOPA, a dopamine precursor that remains the most effective symptomatic treatment [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">257137</post-id>	</item>
	</channel>
</rss>
